Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

por Kazda, Christof M., Bue-Valleskey, Juliana M., Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Wullenweber, Paula, Haupt, Axel, Dahl, Dominik
Publicado 2023

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

por Bue-Valleskey, Juliana M., Kazda, Christof M., Ma, Chenchen, Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Haupt, Axel, Frias, Juan P.
Publicado 2023

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

por Guzman, Cristina B., Duvvuru, Suman, Akkari, Anthony, Bhatnagar, Pallav, Battioui, Chakib, Foster, Wendra, Zhang, Xiaotian Michelle, Shankar, Sudha S., Deeg, Mark A., Chalasani, Naga, Hardy, Thomas A., Kazda, Christof M., Pillai, Sreekumar G.
Publicado 2018

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:12...

por Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.
Publicado 2017